Objective: To investigate the mechanism by which fat-specific transgenic expression of resistin affects fatty acid metabolism in the spontaneously hypertensive rat (SHR). Design: Basal-and adrenaline-stimulated lipolysis, basal-and insulin-stimulated lipogenesis as well as the site (glycerol versus acyl moiety) of glucose incorporated into triglycerides were determined in adipose tissue isolated from SHR-Resistin transgenic and SHR control rats. Results: A moderate expression of transgenic resistin in adipose tissue was associated with significant increase in the FFA/ glycerol ratio during adrenaline-stimulated lipolysis in the SHR-Resistin transgenic rats (3.2770.26) compared to SHR controls (2.1170.10, P ¼ 0.0005). Transgenic SHR also exhibited a significant decrease in FFA re-esterification in adipose tissue (approximately by 23%). Conclusion: These findings raise the possibility that the prodiabetic effects of transgenic resistin may be partly mediated by increased FFA release from adipose tissue due to impaired FFA re-esterification in adipocytes.
Introduction
Resistin, a molecule secreted by fat cells, has been proposed as a possible molecular link between obesity and insulin resistance. 1 To investigate the effects of resistin on lipid and glucose metabolism, we recently derived a novel transgenic strain of spontaneously hypertensive rats (SHR) expressing the mouse resistin gene under control of the fat-specific aP2 promoter. A moderate expression of transgenic resistin in adipose tissue was associated with increased serum fatty acids and muscle triglycerides, impaired skeletal muscle glucose metabolism and glucose intolerance even in the absence of significant changes in serum resistin concentrations. 2 Using a new antibody (Biovendor, Brno, Czech Republic) that detects specifically mouse resistin protein and does not crossreact with rat resistin, we recently confirmed that mouse transgenic resistin is not secreted (unpublished results). These findings suggested that autocrine/intracrine effects of resistin in adipocytes might be inducing the release of free fatty acids (FFA) or other prodiabetic effector molecules that impair glucose metabolism in skeletal muscles. Therefore, in the current studies, we investigated the effects of transgenic resistin on FFA reesterification and release of FFA from epididymal fat tissue isolated from the SHR-Resistin transgenic strain and the SHR control strain.
Methods
Production of resistin transgenic SHR line (SHR-Resistin) was described previously. 2 Measurement of adrenaline-stimulated lipolysis was performed as described previously. 3 Estimation of 14 C-glucose incorporation into neutral lipids and the site (glycerol versus acyl moiety) of glucose incorporated into neutral lipids were determined as described previously. 4, 5 Real-time PCR analysis was used to test for the expression of Pck1 gene in epididymal fat. 2 The upstream primer was 5 0 -cgc cat taa gac cat cca g-3 0 ; the downstream primer was 5 0 -aag tga tgg tga ctc ctg g-3 0 .
Results
As shown in Figure 1 , adrenaline-stimulated release of FFA from epididymal fat was significantly greater in the SHR-Resistin transgenic strain than in the SHR controls, whereas adrenaline-stimulated release of glycerol in the SHR-Resistin transgenic strain was not significantly different compared to SHR controls. In the SHR-Resistin transgenic strain, the FFA/glycerol ratio was approximately 3, which suggests a near total suppression of fatty acid re-esterification as the complete lipolysis of 1 mol of triglyceride yields 1 mol of glycerol and 3 mol of FFA. In the SHR controls, the FFA/glycerol ratio of 2.11 suggests that approximately 30% of the FFA were recycled (2.11/3 ¼ 0.70, i.e. 70% of fatty acids were released and remaining 30% were re-esterified). Data on 14 C-glucose incorporation into total lipids are shown in Figure 2a . Expression of transgenic resistin was associated with significantly decreased incorporation of glucose into the acyl groups (de novo fatty acid synthesis) ( Figure 2b ) and glycerol residue (Figure 2c ) of the lipid molecule. Incorporation of radioactively labeled glucose into glycerol residue is a marker of de novo glycerol synthesis and indirectly of FFA re-esterification. Transgenic resistin was thus associated with a significant suppression (approximately by 23%) of FFA re-esterification in adipose tissue. Figure 2d shows that SHR-Resistin transgenic rats exhibited significantly reduced expression of the Pck1 gene when compared to SHR controls. Transgenic resistin suppresses FA re-esterification M Pravenec et al
Discussion
Several groups have reported that circulating resistin contributes to the pathogenesis of insulin resistance and glucose intolerance by mechanisms that include effects on hepatic glucose production. [6] [7] [8] [9] [10] [11] In the current studies, we concentrated on the role of resistin in lipid metabolism. We tested the hypothesis that resistin might promote release of FFA from adipocytes by suppressing the re-esterfication of FFA into triglycerides. Disordered fatty acid metabolism has long been suspected both as a potential cause and consequence of insulin resistance and impaired glucose metabolism. Triglycerides stored in adipose tissue can be hydrolyzed by hormone-sensitive lipase into FFA and glycerol. Some of the FFA liberated during lipolysis are released from the adipocytes and other FFA are re-esterified into triglycerides. The glycerol-3-phosphate that is required for triglyceride synthesis during re-esterification of FFA can be produced in adipose tissue through two pathways: (a) in the presence of glucose in media or in the postprandial state, glycolysis is a classical source of glycerol-3-phosphate whereas (b) in the absence of glucose in the media or during fasting when glycolysis is suppressed, the glycerol-3-phosphate can be produced by the glyceroneogenesis, 12, 13 where phosphoenolpyruvate carboxykinase (PEPCK) is considered to be a key enzyme in the regulation of glyceroneogenesis and subsequent FFA re-esterification. 14, 15 In the current study, we found that expression of transgenic resistin in adipocytes induced significant reduction of FFA re-esterification. In addition, the expression of the Pck1 gene encoding the PEPCK enzyme was significantly reduced in epididymal fat tissue of the SHR-Resistin transgenic strain compared to SHR controls. Thus, the current findings raise the possibility that transgenic resistin may promote increased release of FFA in part by suppressing their re-esterification in adipocytes, perhaps through inhibition of Pck1 gene expression and subsequently glyceroneogenesis.
In conclusion, the current results suggest that the prodiabetic effects of transgenic resistin may be mediated at least in part by suppressed re-esterification of FFA leading to increased FFA release from adipose tissue.
